Introduction {#Sec1}
============

In 2004, more than 30 years after the proposition that targeting the vascularization of malignant tissues might provide a therapeutic benefit \[[@CR1]\], the first angiostatic drug was approved by the FDA, i.e., bevacizumab (Avastin^®^) \[[@CR2]\]. Currently, bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), is FDA approved for the treatment of metastatic colorectal cancer (mCRC), metastatic renal cell cancer (mRCC), non-small cell lung cancer (NSCLC) and glioblastoma, while its treatment efficacy in other malignancies is still being investigated. In addition, in the last decade the FDA has approved several other angiostatic drugs for the treatment of different malignancies (Table [1](#Tab1){ref-type="table"}). Despite the increasing number of angiostatic drugs targeting different angiogenic pathways \[[@CR3]--[@CR5]\], thus far only limited clinical benefit of angiostatic therapy has been demonstrated. For example, bevacizumab monotherapy in patients with previously treated mCRC resulted in an inferior overall survival (OS) of 10.2 months compared to a OS of 10.8 months with standard chemotherapy (FOLFOX4) \[[@CR6]\], whereas the first-line therapy with sorafenib in patients with mRCC results in a similar progression-free survival as treatment with interferon alpha-2a \[[@CR7]\]. A well-known exception to this is sunitinib which has been shown to improve OS in the first-line treatment of patients with metastatic RCC as compared to interferon alpha \[[@CR8], [@CR9]\].Table 1FDA-approved angiostatic drugs for cancer treatmentDrug (trade name)Main target(s)Cancer type^a^Antibodies Aflibercept (Zaltrap^®^)VEGF/PlGFmCRC Bevacizumab (Avastin^®^)VEGFmCRC, NSCLC, mRCC, Glioblastoma Ramucirumab (Cyramza^®^)VEGFR2Advanced stomach cancer or gastroesophageal junction adenocarcinoma Panitumumab (Vectibix^®^ **)**EGFRmCRC (wt KRAS) Cetuximab (Erbitux^®^)^b^EGFRmCRC (wtKRAS), metastatic non-small cell lung cancer and head and neck cancerSmall molecules Axitinib (Inlyta^®^)VEGF-R1/2/3, PDGFR, c-KITRCC Everolimus (Afinitor^®^)FKBP12/mTORC1RCC, breast cancer, NET Erlotinib (Tarceva^®^)EGFRNSCLC, PC Pazopanib (Votrient^®^)VEGFR-1/2/3, PDGFR-α/β, c-KitRCC, STS Regorafenib (Stivarga^®^)VEGFR-2, TIE-2mCRC, GIST Sorafenib (Nexavar^®^)C-RAF, B-RAF, VEGFR-2/3, PDGFR-β,RCC, HCC, thyroid cancer Sunitinib (Sutent^®^)VEGFR-1/2/3, PDGFR-α/β, c-KitmRCC, imatinib-resistant GIST, progressive NET in the pancreas Thalidomide (Thalomid^®^)Cereblon, unknownMultiple myeloma Vandetanib (Caprelsa^®^)VEGFR-1/2/3, EGFR, RETMedullary thyroid cancer Cabozantinib (Cabometyx^®^)VEGF-R2, c-METAdvanced RCC, medullary thyroid cancer Lenvatinib (Lenvima^®^)VEGF-R1/2/3Advanced RCC, thyroid cancer^a^ *m* metastatic, *CRC* colorectal cancer, *NSCLC* non-small cell lung cancer, *RCC* renal cell cancer, *PC* pancreatic cancer, *NET* neuroendocrine tumors, *STS* soft tissue sarcoma, *HCC* liver cancer, *GIST* gastrointestinal cancer^b^Was also approved by the FDA in 2004 for the treatment of mCRC \[[@CR2]\]

Despite their limited benefit as monotherapeutics, both clinical and preclinical studies have shown that angiostatic drugs can improve the treatment efficacy when combined with other treatments, including chemotherapy \[[@CR10]--[@CR14]\], photodynamic therapy \[[@CR15]--[@CR17]\], immunotherapy \[[@CR18], [@CR19]\], miRNA-based therapy \[[@CR4]\] and radiotherapy \[[@CR13], [@CR20]--[@CR23]\]. Regarding the latter, promising preclinical observations instigated numerous clinical trials exploring the benefit of combining angiostatic drugs with radiotherapy. Five years ago, we evaluated the clinical opportunities and challenges that accompany the combination of radiotherapy with angiostatic therapy \[[@CR24]\]. At that time, over 75 trials were still ongoing. Here, we present an updated overview of the outcome of these clinical trials. In addition, we evaluate the novel insights from these studies and discuss the outstanding questions that new trials should answer in order to improve the clinical benefit of combining radiotherapy with angiostatic treatment.

The rationale behind combining angiostatic drugs with radiotherapy {#Sec2}
==================================================================

At the first sight, the rationale to combine radiotherapy with angiostatic drugs appears counterintuitive since the effect of radiotherapy relies on the presence of oxygen \[[@CR25]\] while angiostatic drugs aim to block tumor oxygenation. Despite this apparent conflict, several preclinical studies have shown that angiostatic treatment can enhance tumor oxygenation, thereby increasing the efficacy of radiation treatment \[[@CR13], [@CR22], [@CR26]--[@CR28]\]. The mechanisms by which angiostatic drugs improve tumor oxygenation are still not fully understood. Initially, it was hypothesized that selective killing of the endothelial cells would reduce their oxygen consumption and increase vascular permeability. This would result in an increased oxygen availability and diffusion into the tumor tissue \[[@CR29], [@CR30]\]. Later studies indicated that angiostatic treatment might improve tumor oxygenation by remodeling of the abnormal and dysfunctional tumor vasculature to a more normal and functional phenotype \[[@CR27], [@CR31]\]. This 'vascular normalization' is hypothesized to result from restoring the balance between pro- and anti-angiogenic signals. It results in more stable vessels, lower interstitial fluid pressure, better perfusion and consequently a better overall tumor oxygenation \[[@CR22], [@CR32]--[@CR34]\]. For example, our previous work has focussed on the role of galectins in tumor angiogenesis and cancer \[[@CR35]--[@CR40]\]. This was instigated by our discovery of galectin-1 as a pro-angiogenic factor that is essential for endothelial cell function during tumor angiogenesis \[[@CR41]--[@CR44]\]. Importantly, we identified galectin-1 as the endothelial cell target of a synthetic angiostatic peptide named anginex \[[@CR41], [@CR45]\]. Treatment of murine tumor models with anginex (or bevacizumab) was shown to improve tumor oxygenation and consequently to enhance the anti-tumor effect of radiotherapy \[[@CR22]\]. This is in line with other preclinical studies which have linked vascular normalization to an enhanced efficacy of radiation treatment \[[@CR13], [@CR27]\]. At the same time, it has been shown that the vascular normalization occurs only transiently and that continuation of angiostatic treatment eventually causes vessel regression and reduced tumor oxygenation \[[@CR22], [@CR31], [@CR34]\]. Hence, adequate scheduling is important to ensure that radiation is applied during the normalization window \[[@CR22]\]. In addition, to what extent vascular normalization occurs in the clinical setting and whether or not it contributes to better tumor oxygenation is still under debate \[[@CR46], [@CR47]\]. While the latter still requires further investigation, the potential effects on tumor oxygenation certainly provide a rationale to combine angiostatic drugs with radiotherapy.

Another rationale to combine angiostatic therapy with radiotherapy is the observation that tumor irradiation can directly affect tumor vascularization, perfusion and oxygenation. Such radiation-induced vascular changes appear to be dependent on the dose-scheduling regime. Based on a literature study, different dose-dependent effects of radiotherapy on the vasculature could be distinguished, i.e., vessel deterioration, vessel preservation and vessel induction \[[@CR48]\]. The latter, i.e., the stimulation of tumor vascularization and perfusion, is predominantly observed during fractionated (low-dose) radiotherapy. For example, Mayr et al. \[[@CR49]\] used contrast enhanced MRI to determine tumor perfusion in cervical cancer patients receiving fractionated radiotherapy (±5 × 2 Gy/week for 4--5 weeks). They observed increased perfusion after 2 weeks of treatment after which a decline in perfusion was observed. A comparable finding was reported by Shibuya et al. \[[@CR50]\] using perfusion CT. Improved tumor perfusion following fractionated irradiation was also reported in other tumor types, including in non-locally advanced rectal tumors (5 × 5 Gy) \[[@CR51]\], and inoperable non-small cell lung tumors (6 × 4.5 Gy) \[[@CR52]\]. In the latter study, the increase in tumor blood volume occurred both at the rim and the center of the tumor albeit to a lesser extent in the tumor center \[[@CR52]\]. We also observed improved perfusion in the center of xenograft colorectal tumors in mice that received 3 weeks of fractionated irradiation (5 × 2 Gy/week) \[[@CR28]\]. Interestingly, the observation that fractionated irradiation can induce tumor tissue perfusion is in line with reports that fractionated radiotherapy can improve tumor oxygenation \[[@CR53], [@CR54]\]. Thus, improved tumor perfusion might represent an additional mechanism of radiotherapy-induced tumor oxygenation, next to previously described mechanisms like decreased oxygen consumption, increased inflammation and reduced tumor volume \[[@CR55]\]. While the improved perfusion and oxygenation might increase the efficacy of subsequent irradiations, our recent findings confirm that the tumor areas with increased perfusion also contained more viable tumor tissue \[[@CR28]\]. Apparently, the improved tumor vascularization and oxygenation can also contribute to tumor cell survival or to tumor regrowth following fractionated radiotherapy. Thus, blocking this effect by angiostatic drugs could improve the efficacy of the radiation treatment.

Altogether, the addition of angiostatic drugs to radiotherapy might be effective by (1) transiently improving tumor oxygenation and/or (2) counteracting radiotherapy-induced tumor (re)vascularization to prevent or delay tumor recurrence. However, it is evident that optimal dose-scheduling of both treatment modalities is the key to achieve beneficial effects of the combination therapy. After all, dose-scheduling of angiostatic drugs will influence whether and when vessel normalization occurs, thereby affecting the efficacy of radiotherapy. At the same time, dose-scheduling of radiotherapy will influence tumor perfusion and oxygenation, thereby affecting the efficacy of angiostatic drugs. All this has been recognized and studied by us and others in different preclinical tumor models \[[@CR22], [@CR23], [@CR56], [@CR57]\]. The current challenge is to translate all these insights into clinically applicable protocols. For this, several outstanding questions have to be answered, especially with regard to dose-scheduling and with regard to the commonality of the observed effects of radiotherapy on tumor vascularization and perfusion. Insights from past, present and future clinical trials on the efficacy of the combination therapy can help to answer these questions.

The past results of combined angiostatic/radiation therapy {#Sec3}
==========================================================

In 2012, we performed an extensive review of the results of clinical trials that combined radiotherapy with angiostatic treatment. The overall conclusion at that time was that this combination treatment generally results in favorable outcomes with regard to tumor response and patients survival \[[@CR24]\]. The observed efficacy appeared to depend not only on the type of drug and the type of tumor but also on the proper scheduling and dosing of both therapies which was in line with preclinical observations. In fact, exploring the optimization of dose-scheduling was identified as an important future challenge, especially since concerns were raised regarding the increased toxicity that is observed in patients who received the combination treatment \[[@CR24], [@CR58], [@CR59]\]. Interestingly, our recent studies in preclinical tumor models indeed show that optimizing the treatment schedule does allow dose reductions without loss of treatment efficacy, i.e., decrease in tumor volume \[[@CR23], [@CR28]\]. This is in line with a previously published mouse study \[[@CR60]\] as well as with several clinical case reports \[[@CR61], [@CR62]\]. However, strong clinical evidence that dose reduction does result in lower toxicity while not affecting the efficacy of the combination treatment is still lacking.

Collectively, past clinical trials confirmed the preclinical findings that the combination of angiostatic drugs with tumor irradiation could provide opportunities to improve patient outcome. However, the combination therapy was found to be associated with increased toxicity profiles which pointed toward the need to improve dose-scheduling.

The present progress in combined angiostatic/radiation therapy {#Sec4}
==============================================================

The 2012 paper by Kleibeuker et al. listed 78 ongoing clinical trials combining angiostatic drugs with radiotherapy \[[@CR24]\] which was illustrative of the expectations regarding the clinical benefit of this combination treatment strategy. At present, 45 of these trials have been completed and 19 trials are still ongoing. In addition, four have been terminated due to either an insufficient number of participants, unacceptable toxicity or withdrawal of support from the sponsor, whereas the remaining studies did not have a recent status update (Table [2](#Tab2){ref-type="table"}). Out of the 45 completed trials, 22 published study results in PubMed-indexed journals. Of note, the majority of these published trials, i.e., 18, evaluated the combination of (chemo)radiotherapy with bevacizumab (Table [3](#Tab3){ref-type="table"}). Since we recently discussed the opportunities of combining radiotherapy with another widely used angiogenesis inhibitor, i.e., sunitinib \[[@CR63]\], we will focus here mainly on bevacizumab.Table 2Updated list of ongoing clinical trials in 2012TrialPhaseDisease^a^Scheduling^b^Radiotherapy regime^c^ChemotherapyStatus^d^Remark/publicationBevacizumab NCT00570531IIEC (locoregional)Conc25 × xGyPaclitaxel/cisplatin/5-FU4Insufficient number of participants NCT00354679IIES (LA)Neo/conc30 × xGyCisplatin/irinotecan1Results, unpublished NCT01332929IBrain metastasesNeo/conc15 × 2 or 10 × 3 Gy1Levy et al. \[[@CR109]\] NCT00817284IIGBMNeo/conc30 × 2 GyTemozolomide vs irinotecan1No results/publications NCT00805961IIGBM (first-line treatment)Conc/adj30 × 2 GyTemozolomide/everolimus1Hainsworth et al. \[[@CR77]\] NCT00590681IIGBM (ND)Adj30--33 × 1.8--2.0 GyTemozolomide1No results/publications NCT01186406IIGBM (ND)Conc/adj30 × 2 GyGliadel/temozolomide2Results, no publications NCT00884741IIIGBM (ND)Conc/adj30 × xGyTemozolomide1Gilbert et al. \[[@CR65]\] NCT00943826IIIGBM (ND)Neo/conc30 × 2 GyTemozolomide1Chinot et al. \[[@CR64]\] NCT01102595IIGBM (unresectable)Neo/conc30 × 2 GyTemozolomide1No results/publications NCT01022918IIGBM (unresectable)Neo/adj30 × 2 GyTemozolomide/irinotecan1Chauffert et al. \[[@CR72]\] NCT00597402IIGBM and gliosarcomasConc/adj33 × xGyTemozolomide/irinotecan1Results, no publications NCT01209442IIGBMConc/adj60 Gy in 2 weeksTemozolomide2No results/publications NCT01013285IIGBM or gliosarcoma (ND)Conc/adj30 × xGyTemozolomide2No results/publications NCT01443676IIGBM (eldery patient)ConcUnknown1No results/publications NCT00369122IICervical cancer (LA)Conc45 Gy in 25 fractionsCisplatin1Results, unpublished NCT00545792IIGynecological cancer (recurrent)Conc45 Gy in 25 fractions1Viswanathan et al. \[[@CR78]\] NCT00703976IIHNSCC (LA)Conc35 × 2 GyCetuximab/pemetrexed1No results/publications NCT00281840IIHNSCC (stage III/IV)Conc/adj40 × 1.8 GyDocetaxel1Yao et al. \[[@CR76]\] NCT01004874IIMalignant glioma (grade IV)Conc/adjStandard Rth for 6.5 weeksTemozolomide/topotecan2Results, no publications NCT00782756IIMalignant glioma (ND)Neo/conc/adj3 × xGy/week for 2 weeksTemozolomide2No results/publications NCT01478321IIHigh-grade recurrent malignant gliomaConc/adj25 × xGyTemozolomide3No results/publications NCT00387374IINCSLC (stage IIIB/IV unresectable)Adj10 × xGyCarboplatin/paclitaxel1No results/publications NCT00896181IINPC (advanced)Neo/conc30--35 × xGyDoxatel/cisplatin/5-FU/carboplatin3No results/publications NCT00408694IINPC (stage IIB--VB)Conc/adj33 × 2.12 GyCisplatin/5-FU1Lee et al. \[[@CR74]\] NCT00334815I/IINSCLC (stage III irresectable)Conc35 × xGyCisplatin/etoposide2Results, unpublished NCT00402883IINSCLC (stage III)Conc/adj35 × 1.8 GyPemetrexed/carboplatin4Toxicity NCT00578149IINSCLC (stage III)Conc/adj35 × xGyPaclitaxel/carboplatin1No results/publications NCT00307723I/IIPancreatic cancerConc35 × xGyOxaliplatin/5-FU4Insufficient number of patients NCT00336648IIPancreatic cancerConc/adj28 × 1.8 GyGemcitabine1No results/publications NCT00460174IIPancreatic cancer (localized)Neo15 × 2.4 GyGemcitabine1Rezai et al. \[[@CR110]\] NCT00557492IIPancreatic cancer (potentially resectable)Conc/adj10 × 3 GyGemcitabine2Results, unpublished NCT00349557IIProstate cancer (high risk)Conc/adjIMRTBicalutamide1No results/publications NCT00321685IIRC (LA non-metastatic)Conc28 × 1.8 GyCapecitabine/oxaliplatin (FOLFOX)1Landry et al. \[[@CR73]\] NCT00113230IIRC (LA)Conc28 × 1.8 GyCapecitabine1Results, unpublished NCT01434147IIRC (LA)Neo25 × 1.8 GyCapecitabine/oxaliplatin1No results/publications NCT00557713IIRC (LA)Neo/conc28 × 1.8 GyOxaliplatin/capecitabine5No results/publications NCT00842686IIRC (LA)Neo/conc28 × 1.8 GyCapecitabine5No results/publications NCT00865189IIRC (LA)Neo/conc25 × 1.8 GyFOLFOX/5-FU1Borg et al. \[[@CR71]\] NCT01043484IIRC (localized)Conc25 × 1.8 GyCapecitabine1Salazar et al. \[[@CR75]\] NCT00308516IIRC (stage II/III)Conc/adj28 × 1.8 GyFU/FOLFOX61Spigel et al. \[[@CR83]\] NCT01481545IIRC (poor risk)Conc/adj25 × 1.8 Gy2No results/publications NCT00356031IISarcomaNeo30 × xGy5No results/publications NCT00308529IISCLC (LA)Neo/conc/adj34 × 1.8 GyIrinotecan/carboplatin1Spigel et al. \[[@CR111]\] NCT00387699IISCLC (limited stage)Conc/adj15 × twice daily xGyCisplatin/etoposide1No results/publicationsBevacizumab/erlotinib NCT00393068IIEC (operable)Conc25 × 1.8 Gy5-FU/paclitaxel/carboplatin1Bendell et al. \[[@CR70]\] NCT00720356IIGBM or gliosarcoma (ND)Conc/adj30 × xGyTemozolomide2No results/publications NCT00140556IHNSCC/NPCConc70 Gy in twice daily 1.25 GyCisplatin1Yoo et al. \[[@CR87]\] NCT00392704IIHNSCC (LA)Neo/conc38 × 1.8 GyPaclitaxel/carboplatin/5-FU1Hainsworth et al. \[[@CR112]\] NCT00280150I/IINSCLC (stage III)Conc74 Gy in 35 fractionsCarboplatin1No results/publications NCT00614653IPancreatic cancerConc28 × 1.8 GyCapecitabine1No results/publications NCT00735306I/IIPancreatic cancerConc28 × 1.8 GyRaltitrexed/oxaliplatin/5-FU1Results, unpublished NCT00307736I/IIRC (LA)Conc28 × 1.8 Gy5-FU1Blaszkowsky et al. \[[@CR113]\] NCT00543842I/IIRC (LA)Conc28 × 1.8 GyCapecitabine1No results/publicationsBevacizumab/cetuximab NCT00703976IIHNSCC (LA)Conc/adj35 × 2 GyPemetrexed1No results/publications NCT01262859IIHNSCC (LA)Neo/con35--37 × 2 GyCisplatin4No results/publications NCT00968435IIHNSCC (stage III/IV)Neo/conc70 Gy in 33 fractionsCisplatin1No results/publicationsEndostar/endostatin NCT01158144IINSCLC (LA)Conc30--33 × 2 GyPaclitaxel/carboplatin1Sun et al. \[[@CR104]\] NCT01218594IINSCLC (LA)Neo/conc/adj30--33 × 2 GyDoxatel/cisplatin1Bao et al. \[[@CR102]\] NCT01211002IVNSCLC (LA)Conc30--33 × 2 GyEtoposide/cisplatin5No results/publicationsSorafenib NCT00822848ISoft tissue sarcomaNeo/conc28 Gy in eight fractionsEpirubicin/Ifosfamide2No results/publications NCT00610246ICancer (not eligible for curative treatment)Neo/conc/adjX × xGy1No results/publications NCT00544817IIGBM (postsurgical)Adj30 × 2.0 GyTemozolomide1Hainsworth et al. \[[@CR92]\] NCT00892658IHCCNeo/conc/adjThree fractions in 2 weeks2No results/publications NCT01328223IIHCC (advanced)Conc/adj23--24 × 2.0--2.5 Gy5No results/publications NCT00892424I/IILiver metastasis (unresectable)Neo/conc3 × xGy/week for 2 weeks2No results/publications NCT00609934I/IIRCC with bone metastasisConc/adj10 × 3 Gy1No results/publicationsSU5416 NCT00023725I/IISoft tissue sarcomaNeo/conc/adj25 × xGy1No results/publications NCT00023738I/IISoft tissue sarcomaConc/adj2 cycles of 11 × xGyDoxorubicin/ifosfamide/dacarbazine1No results/publications NCT01308034INon-GIST SarcomasConc30 × xGy2No results/publicationsSunitinib NCT01100177IIGBM (ND)Neo/conc30 × 2 Gy1No results/publications NCT01498835ISoft tissue sarcomaConc28 x 1.8 Gy1Jakob et al. \[[@CR96], [@CR114]\] NCT00753727I/IISoft tissue sarcomaNeo/conc28 × 1.8 Gy5No results/publications NCT00631527IProstate cancerConc40 fractions of xGyHormone therapy1No results/publicationsThalidomide NCT00049361IIBrain metastases (ND)Conc/adj15 × xGyTemozolomide1No results/publications NCT00033254IIIBrain metastasesConc/adj15 × 2.5 Gy1No results/publicationsVandetanib NCT00745732I/IINSCLCNeo/conc15 × 3 or 33--35 × 2 Gy4Sponsor withdrew support^a^Disease: *RCC* renal cell carcinoma, *LA* locally advanced, *HNSCC* head and neck squamous cell cancer, *NSCLC* non-small cell lung cancer, *EC* esophageal cancer, *RC* rectal cancer, *ND* newly diagnosed, *GBM* glioblastoma, *NPC* nasopharyngeal cancer, *HCC* hepatocellular carcinoma, *SCLC* small cell lung cancer^b^Scheduling: scheduling of angiostatic drug to radiotherapy *neo* neoadjuvant, *conc* concurrent, *adj* adjuvant^c^Radiotherapy: Rth is applied at a frequency of 5 days/week unless indicated otherwise. When the dose applied is unknown, this is indicated with × Gy^d^Status: 1 = completed; 2 = active, not recruiting; 3 = recruiting; 4 = terminated/withdrawn; 5 = unknown Table 3Overview of trials combining RTx with bevacizumab published between 2012 and 2017TrialPhaseDisease^a^Scheduling^b^Radiotherapy regime^c^ChemotherapyTreatment benefitReferencesNCT01332929IBrain metastasesNeo/conc15 × 2 or 10 × 3 Gy1/3 versus 11/15^a^\[[@CR109]\]NCT00805961IIGBM (first-line treatment)Conc/adj30 × 2 GyTemozolomide/everolimusYes (PFS)^b^\[[@CR77]\]NCT01186406IIGBM (ND)Conc/adj30 × 2 GyTemozolomideNo (OS and PFS)\[[@CR65]\]NCT00943826IIIGBM (ND)Neo/conc30 × 2 GyTemozolomideYes (PFS), No (OS)\[[@CR64]\]NCT01022918IIGBM (unresectable)Neo/adj30 × 2 GyTemozolomide/irinotecanNo (PFS)\[[@CR72]\]NCT00545792IIGynecological cancer (recurrent)Conc45 Gy in 25 fractionsYes (PFS)\[[@CR78]\]NCT00281840IIHNSCC (stage III/IV)Conc/adj40 × 1.8 GyDocetaxelNo (PFS)^b^\[[@CR76]\]NCT00408694IINPC (stage IIB--VB)Conc/adj33 × 2.12 GyCisplatin/5-FUNo (PFS)^b^\[[@CR74]\]NCT00460174IIPancreatic cancer (localized)Neo15 × 2.4 GyGemcitabineNA^c^\[[@CR110]\]NCT00321685IIRC (LA non-metastatic)Conc28 × 1.8 GyCapecitabine/oxaliplatin (FOLFOX)No (pCR)^b^\[[@CR73], [@CR115]\]NCT00865189IIRC (LA)Neo/conc25 × 1.8 GyFOLFOX/5-FUNo (pCR)^b^\[[@CR71]\]NCT01043484IIRC (localized)Conc25 × 1.8 GyCapecitabineNo (pCR)\[[@CR75]\]NCT00308516IIRC (stage II/III)Conc/adj28 × 1.8 GyFU (conc)/FOLFOX6 (adj)Yes (pCR; DFS)^b^\[[@CR83]\]NCT00307736I/IIRC (LA)Conc28 × 1.8 Gy5-FU/erlotinibYes (pCR)^b^\[[@CR113]\]NCT00308529IISCLC (LA)Neo/conc/adj34 × 1.8 GyIrinotecan/carboplatinNA^d^\[[@CR111]\]NCT00393068IIEC (operable)Conc25 × 1.8 Gy5-FU/paclitaxel/carboplatin/erlotinibNo (pCR)\[[@CR70]\]NCT00140556IHNSCC/NPCConc70 Gy in twice daily 1.25 GyCisplatin/erlotinibYes (OS)^b^\[[@CR87]\]NCT00392704IIHNSCC (LA)Neo/conc38 × 1.8 GyPaclitaxel/carboplatin/5-FU (neo); Paclitaxel/erlotinib (conc)Yes (PFS)^b^\[[@CR112]\]^a^Responders according RECIST in patients treated with increasing dose bevacizumab^b^Compared to historical studies, *NA* not assessed^c^Study was set up to compare different response measures^d^Due to early trial closure related to toxicity

Combining bevacizumab with (chemo)radiotherapy {#Sec5}
----------------------------------------------

In 2014, Gilbert et al. and Chinot et al. published the results of two phase III trials that evaluated whether bevacizumab improves the efficacy of standard chemoradiotherapy for patients with newly diagnosed glioblastoma \[[@CR64], [@CR65]\]. Both studies were initiated based on previous observations in phase I/II trials that suggested a potential benefit of this combination treatment \[[@CR66]--[@CR69]\]. In the trial of Gilbert et al., bevacizumab (or placebo) was added in the fourth treatment week of concurrent radiotherapy (30 × 2 Gy) plus temozolomide, whereas Chinot et al. started bevacizumab (or placebo) already in the first treatment week of radiotherapy (30 × 2 Gy) plus temozolomide. Gilbert et al. found no benefit of bevacizumab in terms of overall survival (OS; 15.7 vs. 16.1 months; HR 1.13) and progression-free survival (PFS; 10.7 vs. 7.3 months; HR 0.79), but reported a worse quality of life and a decline in neurocognitive function in the bevacizumab group. Patients treated with bevacizumab experienced grade 3 or higher adverse events more frequently \[[@CR65]\]. Chinot et al. did observe a prolonged PFS in the bevacizumab group as compared to placebo (10.6 vs. 6.2 months), but also failed to show a significant difference in OS. Again, grade 3 or higher adverse events were more common in the bevacizumab cohort (66.8 vs. 51.3% in the placebo group) \[[@CR64]\]. Of note, since the statistical design of the two trials was not comparable, a direct comparison cannot be made. However, both studies point toward a favorable PFS with the addition of bevacizumab to radiotherapy plus temozolomide in newly diagnosed glioblastoma, especially when combination treatment is initiated at the start of radiotherapy. Unfortunately, the favorable PFS is accompanied with increased toxicity. Thus, it remains to be seen if bevacizumab is really a beneficial addition to the first-line treatment in glioblastoma patients.

Overall, the clinical value of combining bevacizumab with radiotherapy is open for debate, especially since most current trials either report no clinical benefit \[[@CR70]--[@CR76]\] or only a (minor) benefit in PFS or pCR (pathological complete response) \[[@CR77], [@CR78]\]. For example, several phase II studies have been performed in rectal cancer patients based on promising results in phase I trials \[[@CR79], [@CR80]\]. Borg et al. \[[@CR71]\] added bevacizumab to neoadjuvant 5-FU and RT for 46 patients with stage III rectal cancer before total mesorectal excision, evaluating the proportion of patients achieving a pathological complete response (pCR; ypT0N0). The study did not reach a significant difference from expected pCR (10.0%) with a rate of 11.4%. Salazar et al. also failed to show a significant difference in pCR with the addition of bevacizumab to capecitabine-based neoadjuvant chemoradiotherapy (CRT) in 44 patients with stage II/III rectal cancer as compared to 46 patients undergoing only CRT (16 vs. 11%, *p* = 0.54) \[[@CR75]\]. Comparable observations were reported by Dellas et al. \[[@CR81]\]. More recently, Landry et al. reported on the 5-year clinical outcomes of a phase II trial in patients with locally advanced rectal cancer that received preoperative chemoradiation with bevacizumab followed by postoperative chemotherapy (FOLFOX) plus bevacizumab. Despite excellent 5-year OS and DFS, the primary endpoint (30% pCR) was not reached. Moreover, the treatment schedule was associated with substantial neoadjuvant and surgical toxicity. This resulted in low compliance to adjuvant treatment, and therefore, it was recommended to not further explore this combination treatment \[[@CR73]\]. Also Kennecke et al. \[[@CR82]\], who evaluated preoperative bevacizumab treatment added to oxaliplatin, capecitabine and radiation in 42 locally advanced or low rectal cancer patients, suggested that the results of their study did not justify a phase III trial aimed at exploring the benefit of neoadjuvant bevacizumab in rectal cancer. Of note, Spigel et al. \[[@CR83]\] observed an improved pCR rate of 29% in patients with stage II/III rectal cancer who were treated prior to surgery with 5-fluorouracil, bevacizumab and radiotherapy. Also Xiao et al. \[[@CR84]\] reported that sandwich-like neoadjuvant therapy with bevacizumab was safe and effective for locally advanced rectal cancer. Possibly, differences in the timing of surgery, i.e., 2--8 versus 6--8 weeks following chemoradiation could underlie the different observations \[[@CR85]\]. This should be taken into account when further optimizing dose-scheduling of both treatments in rectal cancer. Regarding scheduling, the patient accrual in a single-arm phase II study by Resch et al. \[[@CR86]\] in rectal cancer patients that received bevacizumab concurrent with chemoradiation was terminated due to toxicity. Based on these current results, it can be argued whether the combination of radiotherapy with bevacizumab will provide a clinical benefit to rectal cancer patients.

A similar conclusion can be claimed regarding the combination of radiotherapy and bevacizumab in nasopharyngeal cancer. In a phase II clinical trial by Lee et al. \[[@CR74]\], 44 patients with stage IIB--IVB nasopharyngeal cancer received radiotherapy (33 × 1.2 Gy) in combination with three cycles of bevacizumab and cisplatin, followed by standard adjuvant treatment consisting of fluorouracil in combination with bevacizumab. While the study was designed to test toxicity, the estimated PFS was lower than previously reported in standard therapy (75 vs. 86%). The estimated PFS was also not reached in the study by Yao et al. in patients with locally advanced squamous cell carcinoma of the head and neck that received bevacizumab concurrent with chemoradiation followed by maintenance bevacizumab treatment. Nevertheless, they concluded that the regimen could be further studied in appropriately selected patients, especially those not eligible for cisplatin administration \[[@CR76]\]. Of note, a study combining both bevacizumab and erlotinib with concurrent chemoradiation in head and neck cancer patients appeared to give favorable locoregional control and OS compared to historical controls. It was suggested to further study this in a randomized study \[[@CR87]\].

Altogether, most current studies combining bevacizumab with radiotherapy only show moderate to no clinical benefit at all. In addition, in most studies the combination treatment is associated with increased albeit manageable toxicities. All this is in line with previous observations \[[@CR24]\].

Combining sorafenib with (chemo)radiotherapy {#Sec6}
--------------------------------------------

As mentioned previously, most trials on combining angiostatic drugs with irradiation that were published between 2012 and 2015 involved the addition of bevacizumab to radiotherapy. However, a few trials assessed the combination with other angiostatic drugs. For example, several studies evaluated the addition of the tyrosine kinase inhibitor sorafenib to radiation therapy. Brade et al. \[[@CR88]\] tested the safety of combining sorafenib with SBRT (up to 51 Gy) in liver cancer patients. They observed a high rate of adverse events and DLTs, predominantly in patients in which a high volume of liver was irradiated. This is in line with reports from Goody et al. and Dawson et al. \[[@CR89], [@CR90]\]. Based on these observations, it appears not advisable to combine concurrent sorafenib with SBRT in patients with locally advanced HCC \[[@CR88]\]. Interestingly, Chen et al. \[[@CR91]\] observed more acceptable toxicities when combining concurrent sorafenib with conventional fractionated radiotherapy (2.0--2.5 Gy/fraction up to 60 Gy). Since the response rate appeared similar compared to historical studies of radiotherapy alone, it was concluded that the schedule could be further investigated, albeit with caution \[[@CR91]\]. A comparable conclusion was drawn by Hainsworth et al. \[[@CR92]\] who applied maintenance sorafenib plus temozolomide treatment following fractionated radiotherapy (30 × 2 Gy) plus temozolomide in newly diagnosed glioblastoma patients. Of note, the necessity to combine radiotherapy with sorafenib with caution was further exemplified by the observation that sorafenib prior to radiotherapy can result in reduced liver volumes which might require adjustment of the radiation dose \[[@CR93]\]. In addition, sorafenib treatment was associated with gastrointestinal perforation after radiotherapy in advanced renal cell carcinoma patients \[[@CR94]\]. These findings again illustrate the necessity to gain more insight in the effects of alternative dose-scheduling regimes when combining radiotherapy with angiostatic drugs.

Combining sunitinib with (chemo)radiotherapy {#Sec7}
--------------------------------------------

The opportunities and challenges of this combination treatment were previously reviewed by Kleibeuker et al. \[[@CR63]\]. Here, we briefly discuss some of the latest insights. Recently, Jakob et al. published the results of two phase I trials that explored the feasibility of concurrent sunitinib and radiotherapy for treatment of locally advanced soft tissue sarcoma (STS) prior to surgery \[[@CR95], [@CR96]\]. They observed acceptable toxicity which was comparable to other studies that evaluated the combination of radiotherapy with angiostatic drugs in STS, including pazopanib \[[@CR97]\] and bevacizumab \[[@CR98]\]. Based on favorable responses, all these studies recommended further investigation of the combination treatment in future trials \[[@CR95]--[@CR98]\]. However, a single phase Ib/II study of sunitinib with radiotherapy in soft tissue sarcoma reported unacceptable toxicities as well as increased local relapse rates \[[@CR99]\]. Interestingly, the initial dose of sunitinib used in this study was higher compared to the other studies (50 vs. 25--37.5 mg), which might explain the observed increased toxicity. Horgan et al. explored the feasibility, tolerability and efficacy of sunitinib adjuvant to surgery in locally advanced esophageal cancer patients that received neoadjuvant chemoradiation (irinotecan/cisplatin + 25 × 2 Gy). This regime appeared feasible although it was poorly tolerated. In addition, the treatment did not show any clinical benefit compared to (historical) controls \[[@CR100]\]. All these findings support the previous conclusions by Kleibeuker et al. \[[@CR63]\] that effective combination of radiotherapy with sunitinib relies on better insights in the optimal dosing and scheduling of the combination treatment.

Combining other angiostatic drugs with (chemo)radiotherapy {#Sec8}
----------------------------------------------------------

Besides the trials discussed above, a handful of studies described the combination of additional angiostatic drugs with radiotherapy. For some of these, e.g., SU5416 (semaxanib) and vandetanib, no trial results have been published, possibly because the combination treatment is no longer of interest. For other inhibitors, some information is available. As mentioned above, pazopanib was combined with radiotherapy in soft tissue sarcoma patients \[[@CR97]\]. Based on a dose--escalation study, Haas et al. \[[@CR97]\] concluded that neoadjuvant pazopanib (daily dose of 800 mg daily for 6 weeks) in combination with 50 Gy (25 × 2 Gy) appeared safe, albeit that toxicity should be carefully monitored in future studies. Of note, a case study reported complete remission of gastric and esophageal metastases in a renal cancer patient after treatment with radiotherapy (10 × 3 Gy) and neoadjuvant as well as adjuvant pazopanib \[[@CR101]\]. The study by Haas et al. also reported favorable responses which warrants further studies on the clinical benefit of radiotherapy combined with pazopanib.

Two recent studies evaluated the combination of endostar/endostatin with radiotherapy in NSCLC patients. In the study by Bao et al. \[[@CR102]\], patients with unresectable stage III NSCLC were treated with endostar combined with concurrent chemoradiation (docetaxel/cisplatin + 30--33 × 2 Gy). They reported promising short-term efficacy and local control rates, and the treatment regimen was generally well tolerated \[[@CR102]\]. These findings are in agreement with a previous study in NSCLC patients and warrant future evaluation of this treatment \[[@CR103]\]. On the other hand, Sun et al. evaluated the addition of endostatin to concurrent chemoradiation (carboplatin/paclitaxel + 30--33 × 2 Gy) followed by maintenance chemotherapy + endostatin in patients with unresectable stage III NSCLC. This study was closed early because of unacceptable toxicity, i.e., four out of ten patients presented with grade III pulmonary toxicity \[[@CR104]\].

Collectively, the results of the current studies that evaluate the feasibility to combine angiostatic drugs with radiotherapy have not provided remarkable novel insights regarding this treatment regimen. The occurrence of toxicities remains an issue of concern \[[@CR105]\]. Combining radiotherapy with bevacizumab generally shows limited efficacy while the combination with other angiostatic drugs has shown favorable responses, but still awaits further confirmation in (randomized) clinical studies. Optimization of dosing and scheduling of both treatment modalities remains one of the key future challenges.

The future of combined angiostatic/radiation therapy {#Sec9}
====================================================

Based on preclinical studies as well as on different clinical observations, it still appears feasible that the combination of angiostatic drugs with radiotherapy can be a valuable addition to current therapeutic strategies for cancer patients. At the same time, the insights from past and present clinical trials have made it clear that successful clinical implementation of this combination treatment requires considerable investigations. As evident from our current and previous review, there are a large number of studies ongoing that will help to resolve some of the outstanding questions, especially with regard to feasibility and toxicity of combining different angiostatic drugs with different radiation regimes in a broad spectrum of cancer types. Moreover, several novel trials have been initiated in the past 5 years, for example with bevacizumab (Table [4](#Tab4){ref-type="table"}). The results of all these trials will help to make the necessary steps to bring effective combination therapy to cancer patients.Table 4Newly initiated trials combining bevacizumab with radiotherapy (2012--2017)TrialPhaseDisease^a^Scheduling^b^Radiotherapy regime^c^ChemotherapyStatus^d^NCT01730950IIGBMConcIMRT, 3D-CRT, or proton beam RT 5 days a week for 2 weeksNone2NCT01746238ISTSConc6 weeks, 5 days a weekDoxorubicin3NCT02313272IGBMConcHypofractionated SRTPembrolizumab3NCT01871363IIRCConc25 × 2 GyCapecitabine5NCT01743950IIGBMConc27 × 2 Gy (PRDR)None3NCT01569984IImCRCNeoUp to 60 Gy in six fractions, alternating weekdays for 2 weeksNone1NCT02185352IIBM in BCNeoWBRTEtoposide, cisplatin3NCT01580969Ib/IIGliomaConcIndividually determinedMinocycline3NCT01588431IIHNSCCNeo/conc5 weeks, 70 GyDocetaxel, cetuximab, cisplatin2NCT01818973IIRCNeo/conc5 weeks, 50 GyCapecitabine + oxaliplatin3NCT01554059IIRCNeo/conc5 weeks, 50 Gy5-FU, oxaliplatin1NCT02812641IIECConc4 weeks, 40 GyCisplatin, 5-FU3NCT02672995IBMConcThree fractions, 18--27 GyNone3^a^Disease: *GBM* glioblastoma, *STS* soft tissue sarcoma, *RC* rectal cancer, *mCRC* metastatic colorectal cancer, *BM* brain metastasis, *BC* breast cancer, *HNSCC* head and neck squamous cell cancer, *EC* esophageal cancer^b^Scheduling: scheduling of angiostatic drug to radiotherapy *neo* neoadjuvant, *conc* concurrent, *adj* adjuvant^c^Radiotherapy: radiation is applied at a frequency of 5 days/week unless indicated otherwise. When the dose applied is unknown, this is indicated with × Gy^d^Status: 1 = completed; 2 = active, not recruiting; 3 = recruiting; 4 = terminated/withdrawn; 5 = unknown

One of the most urgent issues to address involves the optimal dose-scheduling of both treatment modalities, not only to improve treatment efficacy, but also because the results from past studies indicated that inadequate dose-scheduling can induce severe toxicities \[[@CR24], [@CR63]\]. With regard to dosing, it is important to explore how alterations in dosing of either treatment affect the toxicity and efficacy of combination therapy. For example, Carlson et al. and Omura et al. explored the addition of bevacizumab to hypofractionated radiotherapy in newly diagnosed glioblastoma patients \[[@CR106], [@CR107]\]. In the latter study, patients received hypofractionated stereotactic radiotherapy (6 × 6 + 4 Gy over 2 weeks) with concurrent and adjuvant temozolomide plus bevacizumab. The regime was identified as safe and was found to have a comparable effect on OS as compared to historical standard treatment. Moreover, the reduced treatment period appears more convenient for cancer patients \[[@CR106]\]. The study by Carlson et al. \[[@CR107]\] also reported that the addition of concurrent/adjuvant bevacizumab to hyperfractionated IMRT (10 × 6 Gy) did not improve OS while a somewhat higher rate of grade 3 toxicity was observed. Nevertheless, these studies provide the first evidence that altered dose-scheduling can be explored in order to improve treatment efficacy. In this light, our recent preclinical results are also of interest. We observed that concurrent combination treatment allowed a 50% reduction in dosing of the angiostatic drug sunitinib without affecting the therapeutic efficacy of conventional fractionated radiotherapy \[[@CR23], [@CR28]\]. Of note, the low dose was also effective in combination with single high-dose irradiation. These observations could provide opportunities to improve combination treatment both in the curative and in the palliative setting. However, the applicability of such approaches in a clinical setting still awaits confirmation.

Apart from dosing, the scheduling of both treatments is also of importance. Different effects have been observed between concurrent and (neo)adjuvant combination of angiostatic drugs with radiotherapy \[[@CR24], [@CR63]\]. Recently, Avallone et al. \[[@CR108]\] reported on differential clinical effects of combining bevacizumab with chemoradiation either concomitantly or sequentially in high-risk locally advanced rectal cancer patients. While the endpoint was reached using the sequential schedule, the concomitant schedule arm was terminated early because of inconsistent activity. Also, toxicity and postoperative complications appeared to be higher after concomitant treatment \[[@CR108]\]. This is illustrative of the importance of optimal scheduling, and it is therefore essential that the effect of scheduling is further explored in future studies.

Finally, future studies should aim to integrate insights on tumor perfusion with the observed response to therapy. As described above, the main rationales to combine angiostatic drugs with radiotherapy are (1) to improve tumor perfusion and oxygenation by vessel normalization and (2) to counteract radiation-induced tumor (re)vascularization. Both aims require different approaches with regard to dose-scheduling. Thus, it is vital in obtain information of tumor perfusion and oxygenation prior to treatment planning but also to monitor changes in these parameters during treatment. This could improve treatment efficacy. Several of the trials that were discussed here also included perfusion measurements or explored (bio)markers that could predict response to therapy. However, it is outside the scope of the current review to discuss the insights of these studies regarding these issues. It suffices to state that the development and implementation of noninvasive imaging techniques to measure perfusion and early tumor responses are important to better explain and/or predict the response to the combination of angiostatic drugs with radiotherapy.

Conclusions {#Sec10}
===========

Despite the limited clinical efficacy of angiostatic drugs as monotherapeutics, there is ample evidence that angiostatic therapy can be valuable when combined with other treatment modalities, including radiotherapy. This involves the beneficial effects of angiostatic drugs on tumor perfusion prior to and during radiation as well as their inhibitory effects on tumor (re)vascularization during or after radiation. Past and present clinical trials that combined angiostatic drugs with radiotherapy indeed showed that this approach can improve therapeutic outcome. However, this is mainly observed in phase I/II trials and actual validation of clinical benefit awaits confirmation in larger randomized phase III trials. Moreover, variable efficacy as well as increased toxicity has been reported when angiostatic drugs are combined with radiotherapy. This is most likely due to non-optimal dosing and inadequate scheduling of both treatment regimes. Thus, exploring the close relation between dose-scheduling represents the key challenge for future research regarding combination treatment. This directly relates to the development of rapid and noninvasive imaging strategies in order to measure tumor perfusion prior, during and after treatment. This will help to optimize current approaches to improve treatment strategies and to make effective combination therapy available for cancer patients in daily clinical practice.
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